Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
The extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to a His-tag and a linker peptide and contains aa substitutions, which generate a binding specificity towards TRAIL receptor 1 (TRAIL-R1; DR4).
Greater than 98% by SDS-PAGE
Induces apoptosis in a concentration range of 20-500ng/ml of TRAIL-R1 (DR4) expressing cell lines (e.g. RAMOS). It is inefficient to kill via TRAIL-R2 (DR5) in Jurkat cells. The activity depends on the relative cellular surface expression of TRAIL-R1 comp
Less than 0.1 EU/µg protein (determined by LAL method).
20 mM HEPES, pH 7.9, 120 mM NaCl, 0.01% Tween20, 1% sucrose, 1 mM DTT
Store at +4°C for immediate use, or aliquot and store at -80°C for at least 6 months. Avoid repeat freeze-thaw cycles.
TNFSF10 / TRAIL is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. This protein binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG.